Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

Brackertz B, Conrad H, Daniel J, Kast B, Krönig H, Busch DH, Adamski J, Peschel C, Bernhard H.

Blood Cancer J. 2011 Mar;1(3):e11. doi: 10.1038/bcj.2011.12. Epub 2011 Mar 18.

2.

Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.

Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.

Clin Cancer Res. 2003 Jun;9(6):2140-50.

3.

Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.

J Biol Chem. 2003 Aug 29;278(35):32892-8. Epub 2003 Jun 18.

4.

Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.

Habif G, Grasset MF, Kieffer-Jaquinod S, Kuhn L, Mouchiroud G, Gobert-Gosse S.

J Proteomics. 2013 Jan 14;78:231-44. doi: 10.1016/j.jprot.2012.09.009. Epub 2012 Sep 24.

PMID:
23017497
5.

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

Li Y, Li H, Wang MN, Lu D, Bassi R, Wu Y, Zhang H, Balderes P, Ludwig DL, Pytowski B, Kussie P, Piloto O, Small D, Bohlen P, Witte L, Zhu Z, Hicklin DJ.

Blood. 2004 Aug 15;104(4):1137-44. Epub 2004 Apr 22.

6.

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.

Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Böhmer FD, Müller-Tidow C, Berdel WE, Serve H.

Blood. 2003 Apr 15;101(8):3164-73. Epub 2002 Dec 5.

7.

p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.

Elf S, Blevins D, Jin L, Chung TW, Williams IR, Lee BH, Lin JX, Leonard WJ, Taunton J, Khoury HJ, Kang S.

Blood. 2011 Jun 23;117(25):6885-94. doi: 10.1182/blood-2010-10-315721. Epub 2011 Apr 28.

8.

Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.

Li L, Reinhardt P, Schmitt A, Barth TF, Greiner J, Ringhoffer M, Döhner H, Wiesneth M, Schmitt M.

Cancer Immunol Immunother. 2005 Jul;54(7):685-93. Epub 2004 Dec 31.

PMID:
15627212
9.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
10.

A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells.

Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C, Fischer T, Wölfel T.

Blood. 2007 Apr 1;109(7):2985-8.

11.

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.

Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA.

Blood. 2013 Mar 14;121(11):2064-73. doi: 10.1182/blood-2012-07-444018. Epub 2013 Jan 15.

12.

FLT3 mutations in acute myeloid leukemia cell lines.

Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.

Leukemia. 2003 Jan;17(1):120-4.

PMID:
12529668
13.

Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.

Liu LL, Zhang DH, Mao X, Zhang XH, Zhang B.

Biochem Biophys Res Commun. 2014 Mar 28;446(1):280-5. doi: 10.1016/j.bbrc.2014.02.094. Epub 2014 Feb 28.

PMID:
24582753
14.

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K.

Blood. 2009 Dec 3;114(24):5034-43. doi: 10.1182/blood-2008-12-196055. Epub 2009 Oct 6.

15.

Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations.

Scholl S, Melle C, Bleul A, Spies-Weisshart B, Kunert C, Höffken K, von Eggeling F.

Leuk Lymphoma. 2007 Dec;48(12):2418-23.

PMID:
18067018
16.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

17.

Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.

Wobus M, Bornhäuser M, Jacobi A, Kräter M, Otto O, Ortlepp C, Guck J, Ehninger G, Thiede C, Oelschlägel U.

Oncotarget. 2015 Nov 17;6(36):38804-15. doi: 10.18632/oncotarget.5661.

18.

Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.

Zheng R, Klang K, Gorin NC, Small D.

Leuk Res. 2004 Feb;28(2):121-6. Erratum in: Leuk Res. 2004 Nov;28(14):1241.

PMID:
14654075
19.

Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells.

Skwarska A, Augustin E, Beffinger M, Wojtczyk A, Konicz S, Laskowska K, Polewska J.

Biochem Pharmacol. 2015 Jun 15;95(4):238-52. doi: 10.1016/j.bcp.2015.04.006. Epub 2015 Apr 17.

PMID:
25896848
20.

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.

Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144. Epub 2010 Feb 16.

Supplemental Content

Support Center